Justice Samuel Alito on Monday granted an administrative stay that temporarily restores the FDA's rule allowing the abortion pill mifepristone to be prescribed online and shipped through the mail, freezing a Fifth Circuit order that had blocked those provisions just days earlier. The stay holds until 5 p.m. on May 11, giving the full Supreme Court time to consider emergency petitions from the drug's two manufacturers.
The move does not resolve the underlying legal fight. It parks the case in neutral while the justices decide whether to intervene more broadly. But the procedural maneuvering masks a much larger question: whether the FDA acted lawfully when it loosened safety requirements for a drug that ends pregnancies, and whether states like Louisiana have the right to push back.
This is the second time the mifepristone battle has reached the Supreme Court. In 2024, the justices unanimously rejected a challenge brought by anti-abortion doctors and medical groups, ruling those plaintiffs lacked standing to sue the FDA. Louisiana then picked up the fight itself, and found a more receptive audience at the Fifth Circuit.
The FDA first approved mifepristone in 2000. For years the agency required in-person dispensing and limited how far into a pregnancy the drug could be used. Starting in 2016, the FDA began relaxing those safeguards, expanding the pool of providers who could prescribe the pill, extending the gestational window, and lifting the requirement that patients pick up the drug in person.
During the COVID-19 pandemic, the agency suspended enforcement of the in-person dispensing rule altogether. It then concluded that mifepristone "may be safely used without in-person dispensing." In 2023, the FDA formalized the change, allowing telehealth prescriptions and mail delivery nationwide.
Louisiana, which banned abortion with narrow exceptions after the Supreme Court overturned Roe v. Wade in 2022, filed a federal lawsuit challenging the FDA's mail-delivery rule. The state went further in 2024, enacting a law that designates both mifepristone and misoprostol as controlled substances and criminalizes possession without a prescription.
A federal district court in Louisiana paused the litigation in April, which had the practical effect of keeping the FDA's loosened rules in place while the agency reviewed the drug's safety. Louisiana officials appealed.
On Friday, a unanimous panel of the U.S. Court of Appeals for the Fifth Circuit sided with the state and temporarily blocked the 2023 rule. The panel found that the FDA's action "injures Louisiana by undermining its laws protecting unborn human life and also by causing it to spend Medicaid funds on emergency care for women harmed by mifepristone."
The standing question has been the legal fault line in every round of this litigation. The Supreme Court tossed the 2024 case precisely because the anti-abortion doctors who brought it could not show a concrete, personal injury. Louisiana offered something different: a Medicaid bill.
The Fifth Circuit panel pointed to two women who received the abortion pill from an out-of-state provider and later required emergency-room care covered by Louisiana's Medicaid program. That financial injury, the court said, gave the state a direct stake in the outcome.
The panel put the point bluntly: "Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is [a] human being from the moment of conception and is, therefore, a legal person.'"
That reasoning matters. If the Supreme Court ultimately agrees that a state's Medicaid expenditures can establish standing, it opens a durable pathway for abortion-restricting states to challenge federal drug-approval decisions, a route the 2024 ruling had seemed to close.
Danco Laboratories, the brand-name manufacturer of mifepristone, and GenBioPro, which makes a generic version, filed emergency applications within hours of the Fifth Circuit's Friday order. Danco's petition, docketed as No. 25A1207, argued that the appellate ruling "injects immediate confusion and upheaval into highly time-sensitive decisions."
CBS News reported that Danco told the justices the Fifth Circuit's order "forces patients, providers, and pharmacies into immediate uncertainty, with no transition period and no practical guidance."
Danco's filing painted a picture of clinical chaos:
"Patients who have appointments, as soon as this morning, are in limbo. Providers who have already screened, counseled, and prepared patients for care may have to stop midstream, potentially unable to complete treatment plans that were set in motion days earlier."
GenBioPro's filing, docketed as No. 25A1208, used similar language, claiming the Fifth Circuit had "unleashed regulatory chaos." The company argued that patients and clinicians had relied on mail dispensing for years, "particularly for women from rural areas and those for whom transportation, childcare, or occupational constraints make it difficult to see providers in person."
Both manufacturers asked the Supreme Court not only to freeze the Fifth Circuit's order but to take up the case on the merits and issue a definitive ruling.
Alito, who handles emergency matters from the Fifth Circuit, granted the administrative stay and set a Thursday deadline for Louisiana officials to respond. The Washington Examiner reported that the stay pauses the Fifth Circuit's ruling through May 11, restoring the status quo that existed before Friday's order.
An administrative stay of this kind is procedural, not substantive. As Breitbart noted in its coverage, such a stay "is not in any way a reflection on the legal merits of the case." It simply buys time for the full Court to read the briefs, consider the arguments, and decide whether to act.
Justice Alito, now deep into his tenure on the Court, has been at the center of the most consequential abortion-related rulings in a generation. His authorship of the Dobbs decision returned the abortion question to the states. The mifepristone litigation tests whether that return is real, or whether federal agencies can effectively override state abortion bans by mailing pills across state lines.
Supporters of the FDA's relaxed rules frame the issue as one of patient access and regulatory stability. GenBioPro warned that "patients nationwide may face delay or denial of access to time-sensitive medical care, supply-chain disruptions, and attendant health risks" if the Fifth Circuit's order stands.
But Louisiana's argument cuts to a harder question. If a state bans abortion, and the federal government allows a pill that terminates pregnancies to be mailed directly to patients in that state, what does the ban actually mean? The Fifth Circuit's standing analysis, built on real Medicaid costs from real emergency-room visits, gives that question legal teeth.
The earlier round of litigation had stalled partly because the plaintiffs were doctors who claimed hypothetical injuries. Louisiana brought receipts. Two women. Two ER visits. Two Medicaid claims. The Fifth Circuit found that sufficient. Whether the Supreme Court agrees will shape the next chapter of post-Dobbs abortion law.
The broader procedural history adds another layer. Just The News reported that a Texas district judge had earlier ruled the FDA did not properly review safety concerns when it first approved mifepristone in 2000, and that the Fifth Circuit had subsequently allowed the drug to remain on the market while imposing distribution limits, a partial compromise that satisfied neither side.
The Supreme Court has repeatedly been drawn into these disputes at the emergency-application stage, a pattern that reflects both the urgency of the underlying questions and the inability of lower courts to settle them durably. The justices have faced a growing docket of high-stakes emergency petitions on matters ranging from immigration policy to election law.
Louisiana officials must file their response by Thursday. After that, the full Supreme Court will decide whether to extend the stay, let the Fifth Circuit's order take effect, or, as both drugmakers have requested, take up the case for full briefing and oral argument.
If the Court agrees to hear the merits, it would mark the second time in three years that the justices have confronted the legal status of the nation's most widely used abortion drug. The first time, they sidestepped the substance by ruling on standing. Louisiana's Medicaid-based theory of injury may force a different outcome.
The administrative stay expires at 5 p.m. on May 11. Between now and then, the Court will signal whether this fight ends quickly or becomes the next landmark case on its docket.
States that ban abortion have every right to ask why the FDA gets to override their laws by mail. That question deserves a real answer, not another procedural punt.
